pmc logo image
Logo of gutGutCurrent TOCInstructions to authors

Formats:

Gut. 1985 June; 26(6): 599–602.
PMCID: PMC1432764
Maintenance therapy: a two year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence.
A G Morgan, C Pacsoo, and W A McAdam
Abstract
Eighty two patients with an endoscopically healed gastric ulcer, were treated for two years with either Caved-S tablets, two twice daily or cimetidine 400 mg at night. During the first year, 12% (four out of 34) of the Caved-S group and 10% (four out of 41) of the cimetidine group had an ulcer recurrence. By the end of the second year, the recurrence rate was 29% (nine out of 31) in the Caved-S group, and 25% (eight out of 32) for the cimetidine group. Ulcer relapse occurred frequently in patients with either a dyspeptic history of over six months (p less than 0.05), or a past history of a gastric ulcer (p less than 0.001). Ulcers recurred rapidly after maintenance therapy; Caved-S two out of 22; cimetidine seven out of 23, within four months (NS). This study shows that long term maintenance therapy is safe and reasonably effective. The high recurrence rate after stopping treatment suggests that therapy in high risk or elderly patients should be for life.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (399K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Morgan AG, McAdam WA, Pacsoo C, Darnborough A. Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. Gut. 1982 Jun;23(6):545–551. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. [PubMed]
  • Machell RJ, Ciclitira PJ, Farthing MJ, Dick AP, Hunter JO. Cimetidine in the prevention of gastric ulcer relapse. Postgrad Med J. 1979 Jun;55(644):393–395. [PubMed]
  • Jensen KB, Møllmann KM, Rahbek I, Madsen JR, Rune SJ, Wulff HR. Prophylactic effect of cimetidine in gastric ulcer patients. Scand J Gastroenterol. 1979;14(2):175–176. [PubMed]
  • Hentschel E, Schütze K, Weiss W, Rüdiger E, Judmair G, Reichel W, Kerstan E, Horton J. Effect of cimetidine treatment in the prevention of gastric ulcer relapse: a one year double blind multicentre study. Gut. 1983 Sep;24(9):853–856. [PubMed]
  • Barr GD, Kang JY, Canalese J, Piper DW. A two-year prospective controlled study of maintenance cimetidine and gastric ulcer. Gastroenterology. 1983 Jul;85(1):100–104. [PubMed]
  • Alstead EM, Ryan FP, Holdsworth CD, Ashton MG, Moore M. Ranitidine in the prevention of gastric and duodenal ulcer relapse. Gut. 1983 May;24(5):418–420. [PubMed]
  • Dronfield MW, Batchelor AJ, Larkworthy W, Langman MJ. Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects. Gut. 1979 Jun;20(6):526–530. [PubMed]
  • Baron JH, Alexander-Williams J, Bennett JR. Cimetidine and duodenal ulcer. Br Med J. 1979 Jan 20;1(6157):169–173. [PubMed]